BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Syed YY. Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs 2020;80:315-22. [DOI: 10.1007/s40265-020-01263-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Laface C, Fedele P, Maselli FM, Ambrogio F, Foti C, Molinari P, Ammendola M, Lioce M, Ranieri G. Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities. Cancers (Basel) 2022;14:4028. [PMID: 36011021 DOI: 10.3390/cancers14164028] [Reference Citation Analysis]
2 Aghanejad A, Bonab SF, Sepehri M, Haghighi FS, Tarighatnia A, Kreiter C, Nader ND, Tohidkia MR. A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors. Int J Biol Macromol 2022;207:592-610. [PMID: 35296439 DOI: 10.1016/j.ijbiomac.2022.03.057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333 [DOI: 10.12998/wjcc.v10.i11.3321] [Reference Citation Analysis]
4 Ansari MJ, Bokov D, Markov A, Jalil AT, Shalaby MN, Suksatan W, Chupradit S, Al-Ghamdi HS, Shomali N, Zamani A, Mohammadi A, Dadashpour M. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Commun Signal 2022;20:49. [PMID: 35392964 DOI: 10.1186/s12964-022-00838-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
5 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Choucair K, Kamran S, Saeed A. Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy. Onco Targets Ther 2021;14:5521-32. [PMID: 35002257 DOI: 10.2147/OTT.S268309] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Qing X, Xu W, Zong J, Du X, Peng H, Zhang Y. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 2021;9:64. [PMID: 34419152 DOI: 10.1186/s40364-021-00319-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang X, Ge Y, Shi M, Dai H, Liu W, Wang P. Protein kinase N1 promotes proliferation and invasion of liver cancer. Exp Ther Med 2021;21:651. [PMID: 33968181 DOI: 10.3892/etm.2021.10083] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Novy Z, Janousek J, Barta P, Petrik M, Hajduch M, Trejtnar F. Preclinical evaluation of anti-VEGFR2 monoclonal antibody ramucirumab labelled with zirconium-89 for tumour imaging. J Labelled Comp Radiopharm 2021;64:262-70. [PMID: 33818828 DOI: 10.1002/jlcr.3909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yang S, Chen C, Qiu Y, Xu C, Yao J. Paying attention to tumor blood vessels: Cancer phototherapy assisted with nano delivery strategies. Biomaterials 2021;268:120562. [PMID: 33278682 DOI: 10.1016/j.biomaterials.2020.120562] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
11 Pu J, Wang J, Qin Z, Wang A, Zhang Y, Wu X, Wu Y, Li W, Xu Z, Lu Y, Tang Q, Wei H. IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism. Front Oncol 2020;10:578816. [PMID: 33224879 DOI: 10.3389/fonc.2020.578816] [Cited by in Crossref: 8] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
12 Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, Hashem AM. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Front Immunol 2020;11:1986. [PMID: 32983137 DOI: 10.3389/fimmu.2020.01986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 46] [Article Influence: 8.5] [Reference Citation Analysis]
13 Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188391. [PMID: 32659252 DOI: 10.1016/j.bbcan.2020.188391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
14 Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 2020;51:100702. [DOI: 10.1016/j.drup.2020.100702] [Cited by in Crossref: 13] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]